ᖃᓄᐃᑉᐱᑖᕐ
Qanuippitaa?

ᐃᐱᓂᐊᓕᕐᑕᓃᑦ:
ᐃᐱᓂᐊᕐᓃᑦ *Asthma, Wheezing* ᐊᒻᒪᓗ ᖁᓄᓪᓕᓇᕐᑐᑦ *(Allergies)* ᑲᒃᑲᓛᓄᑦ ᖃᓄᐃᒍᑕᐅᓲᑦ ᐃᓪᓗᑉ ᐃᓗᐊᓂ ᐊᓂᕐᑎᓇᔭᒥᓂᑦ

ᐊᓂᕐᑎᓇᓂᕐᒥᓂᒃ ᖃᓄᐃᒍᑎᖃᕐᒪᖔᑕ ᖃᐅᔨᓴᕐᑕᐅᒋᐅᑦᓯᐊᓂᕐᒥᔪᑦ ᓄᓇᕕᒻᒥ 2004-ᒍᑎᓪᓗᒍ (1023) ᐃᓄᐃᑦ ᕿᑐᖅᒪᖕᒋᑦ ᐅᑭᐅᓛᑦ 0-ᒥᑦ 14-ᒍᑦ. ᐃᐱᓂᐊᓕᕐᑕᓂᕐᒥᒃ ᖃᐅᔨᒪᐅᑎᑦᓴᐅᓂᐊᕐᑐᓂᒃ ᐊᒻᒪᓗ ᐃᐱᓂᐊᓕᕐᑕᓂᐅᓲᒥᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ (asthma) ᐊᐱᕐᓯᑕᐅᒍᑎᖃᕐᑲᑦᑕᑎᓪᓗᒋᑦ ᐃᓪᓗᒥᐅᖃᑎᓕᒃ, ᐊᖓᔪᖅᑳᓇᔭᐅᔪᖅ, ᐊᓂᕐᑎᓇᓂᕐᒥᓂᒃ ᖃᓄᐃᒍᑎᖃᓲᒍᒻᒪᖔᑕ ᕿᑐᖅᒪᖕᒋᑦ ᐃᓘᓐᓄᓘᓕᖓᔪᑎᒍᑦ ᐊᐱᕐᓲᑎᑎᒍᑦ ᑎᔭᐅᓂᓕᓐᓄᑦ ISAAC. ᐊᓯᖕᒋᓐᓂᓗ ᐊᐱᕐᓯᑕᐅᖃᑦᑕᓯᑎᒃ ᐊᓇᕐᑐᐅᑉ ᐃᓗᐊᓃᑦᑐᓂᒃ ᐊᐱᕐᓯᑕᐅᒍᑎᖃᕐᓯᑎᒃ ᐊᕙᑎᒥᑦᑕᒥᓂᓪᓗ.

ᖃᐅᔨᓴᐅᑎᕕᓂᑎᒍᑦ ᖃᐅᔨᔭᐅᓯᒪᔪᑦ ᐃᐱᓂᐊᓲᒍᓂᕐᓴᐅᒋᐊᖕᒋᑦᑕ ᓇᓗᓐᒃᑯᑕᓕᓐᓂᒃ (Wheezing, persisitent wheezing and severe wheezing) ᐱᖓᓱᕕᓪᓗᐊᑐᒥᒃ ᓯᑕᒪᕕᓪᓗᐊᑐᒥᓪᓘᓐᑦ ᐅᑭᐅᓛᑦ 0-ᒥᑦ 4-ᒍᑦ ᐅᑦᑐᕋᐅᑎᒋᔭᐅᑎᑦᓯᒋᑦ ᐅᑭᐅᓕᓐᓄᑦ 5-ᒥᑦ 14-ᒍᑦ (14.5% vs. 3.4%). ᐅᑦᑐᕋᐅᑎᒋᔭᐅᑎᑦᓯᒋᑦ ᖃᓪᓗᓈᑦ ᓄᓇᖓᓂᒥᐅᓄᑦ ᑯᐯᒻᒥᐅᓄᒃ ᐊᓯᖕᒋᓐᓄᓗ ᐊᒥᓱᓄᑦ ᓄᓇᕐᔪᐊᒥᐅᓄᑦ, ᐃᓄᐃᑦ ᕿᑐᖅᒪᖕᒋᑦ ᒥᑭᓂᕐᓴᑦ ᐃᐱᓂᐊᓲᒍᓂᕐᓴᑦ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ (wheezing) ᐊᒻᒪᓗ ᐊᖓᔪᑦᓲᑦ ᕿᑐᖅᒪᐅᔪᑦ ᐃᐱᓂᐊᓲᒍᖕᒋᓂᕐᓴᐅᑎᓪᓗᒋᑦ. ᐅᑭᐅᓛᑦ 5-ᒥᑦ 14-ᒍᑦ ᐃᓄᐃᑦ ᕿᑐᖅᒪᖕᒋᑦ ᐊᕙᓗᐊᑲᓴᖕᒋᑦ ᐃᐱᓂᐊᓲᒍᓂᕐᓴᐅᑉ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ (wheezing) ᖃᓪᓗᓈᑦ ᕿᑐᖅᒪᖕᒋᓐᓂᑦ ᑯᐯᒻᒥᐅᑦ ᐅᑭᐅᓛᑦ 9-ᒥᑦ 13-ᒍᑦ, ᐊᑦᔨᒋᔭᐅᓂᕐᓴᐅᓯᑎᒃ ᓯᓚᕐᔪᐊᓕᒫᒥ ᐃᐱᓂᐊᓕᕐᑕᓲᓄᑦ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ (asthma). ᖁᐸᕐᒍᑦᑕᐅᖅ, ᐃᓅᓯᓕᒫᒥᓂ ᐃᐱᓂᐊᓕᕐᑕᓲᑦ ᐅᑭᐅᓘᑦ ᐃᐱᓂᐊᓕᕐᑕᓗᑭᓲᑦ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ (asthma) ᐃᓄᐃᑦ ᕿᑐᖅᒪᖕᒋᑦ ᐅᑭᐅᓛᑦ 5-ᒥᑦ 14-ᒍᑦ ᒪᕿᕕᓪᓗᐊᑐᒥᒃ ᐃᐱᓂᐊᓕᕐᑕᑲᑦᑕᓂᕐᓴᐅᓲᒍᕐᑐᑦ ᐅᑭᐅᓕᓐᓂᑦ 0-4ᒍᑦ.

5.6%-ᑐᐃᓐᓇᖕᒋᑦ ᑲᒃᑲᓛᑦ ᖁᓄᓪᓕᑕᓲᑦ, ᐃᐱᓂᐊᓕᕿᐅᑎᒋᖃᑦᑕᓯᒋᑦ ᓇᓗᓐᒃᑯᑕᓕᓐᓂᒃ asthma, persistent or severe wheezing. 50%-ᖕᒋᑦ ᑲᒃᑲᓛᑦ ᐃᐱᓂᐊᓕᕐᑕᓲᒍᑐᐊᕐᒥᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ wheezing ᐃᕐᖃᑎᑕᕕᓂᐅᓚᐅᔪᕐᑐᑦ ᐃᐱᓂᐊᓕᕐᑕᓇᒃᑯᑎᓂᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ asthma ᐅᑦᓘᓂ ᒪᕐᑮᓂ ᖃᐅᔨᓴᕐᓂᖃᓚᐅᕐᑎᓇᒍ. ᐃᓄᐃᑦ (ᐃᓄᒻᒪᓈᑦ ᑲᒃᑲᓛᑦᓗ ᑲᑎᑦᓯᑎᒃ) ᐃᐱᓂᐊᓕᕐᑕᓈᒃᑯᑎᑦᓴᓂᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ asthma ᐃᕐᖃᑎᑕᐅᓂᓇᖕᒋᖓ 5.3% -ᒍᖅ.

ᐃᓄᐃᑦ ᐊᓇᕐᕿᖕᒋᓐᓂ 84.1%-ᓂ ᑐᑉᐸᕐᕕᐅᑕᓕᓲᒍᖅᑦ. ᐃᐱᓂᐊᓕᕐᑕᕿᑕᐅᓲᒍᒻᒪᖔᑕ ᓇᓗᓐᒃᑯᑕᓕᓐᓂᒃ asthma or wheezing ᑐᑉᐸᕐᑕᐅᔫᓪᓘᓐᑦ ᐳᔪᖓᓄᑦ ᐃᐱᓂᐊᓕᕐᑕᓂᖅ ᖃᐅᔨᔭᐅᓯᒪᖕᒋᑐᖅ. ᐃᐱᓂᐊᓕᕐᑕᖃᑦᑕᓂᕐᕐᑯᑦ ᓇᓗᓐᒃᑯᑕᓕᓐᓂᒃ asthma or wheezing ᕿᑐᖅᒪᐅᔪᑦ ᐅᓄᕐᓂᖃᕐᓗᐊᕐᒥᒃ ᖃᑦᓯᑐᐃᓐᓇᓂᒃ ᐅᑭᐅᓛᑦ 0-14-ᒍᑦ ᐃᓪᓗᒥᐅᖃᑎᒋᔭᐅᔪᑦ.

ᓇᐅᓕᒫᓂᒃ ᐃᓗᓯᓕᓇᓂᑎᒍᑦ ᑕᑯᓐᓇᓯᒋᑦ, ᑕᒪᒃᑯᐊ ᖃᐅᔨᔭᐅᓯᒪᔪᑦ ᕿᓪᓕᑐᕐᑕᐅᓇᑦᓯᐊᐳᑦ. ᐅᑭᐅᓛᑦ 5-ᒥᑦ 14-ᓄᑦ ᑲᒃᑲᓛᑦ ᖃᓄᐃᒍᑎᖃᓗᐊᓕᐅᔪᖅᒋᑐᑦ ᖁᓄᓪᓕᑕᕐᑐᓄᑦ ᖃᓄᐃᒍᑕᐅᓲᓂᒃ ᐅᑯᑉᓘᓐᓂᑦ ᐃᐱᓂᐊᓕᕐᑕᕿᑕᐅᓲᓂᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ asthma, ᖃᐅᔨᓴᑦᓯᑕᓗ ᐃᓄᐃᑦ ᐊᓇᕐᕿᒥᓂ ᑐᑉᐸᕐᑕᒐᓕᑦᓯᒍᕐᑕᐅᓲᓂᒃ ᐊᒻᒪᓗ ᐊᓪᓚᖕᒍᕐᑎᑕᐅᓯᒪᔪᕐᑲᓚᐅᔪᓚᓂ ᐱᑦᓯᐊᖕᒋᑦᑐᑯᑦ ᓯᕐᑕᐅᓯᒪᒻᒪᖔᑕ ᐃᓄᐃᑦ ᕿᑐᖅᒪᖕᒋᑦᑕ ᐃᓪᓗᕿᑦᓴᓂᕐᒍᑦ. ᑭᓯᐊᓂ, ᖃᐅᔨᓴᐅᑎᕕᓂᑎᒍᑦ ᖃᐅᔨᔭᕕᓃᑦ ᐅᑭᐅᓛᑦ 0-14-ᓂᒃ ᐅᑭᐅᓛᑦ ᐃᐱᓂᐊᓕᕐᑕᓂᓇᖕᒋᖓ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ wheezing, ᐅᓄᕐᓂᖕᒋᑦᑕᓗ ᑲᒃᑲᓛᑦ ᐃᐱᓂᐊᓕᕐᑕᓲᑦ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ persistent and severe wheezing, ᐊᒻᒪᓗ ᐃᐱᓂᐊᓕᕐᑕᓈᒃᑯᑎᓂᒃ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ asthma ᐃᕐᖃᕐᑲᑦᑕᓃᑦ ᖃᐅᔨᒪᐅᑎᒋᔭᐅᒍᓐᓇᐳᑦ ᐃᑯᓪᓕᑎᒐᓯᐊᓇᐊᒥᒃ ᐱᔭᓇᐊᑐᔫᓂᖓᓂᒃ ᐃᐱᓂᐊᓕᕐᑕᓯᒋᑦ. ᐱᑦᔪᑎᐅᓂᕐᐸᐅᑐᐃᓐᓇᓇᐊᓛᑦ ᐃᒻᒪᓯᒪᓃᑦ ᐳᕙᒃᑯᑦ. ᖃᐅᔨᓴᕐᑕᐅᓯᐊᓇᐊᕐᑲᕐᕐᑯᑦ ᐋᓐᓂᐊᓯᐅᕐᑕᐅᒍᑕᐅᒋᐊᕐᑲᕐᓂᖓ ᐃᐱᓂᐊᓕᕐᑕᓂᐅᑉ ᓇᓗᓐᒃᑯᑕᓕᒻᒥᒃ wheezing, ᐊᒻᒪᓗ ᐃᑯᓪᓕᑎᑕᐅᓚᓯᐊᕐᓂᖓ ᓇᓗᓐᒃᑯᑕᓕᐅᑉ asthma ᐃᓄᐃᑦ ᐊᑯᕐᖓᓂ.

———————

ᐳᐳᐳ

ᐊᓪᓚᑐᕕᓃᑦ

> Pierre Lajoie, Benoit Lévesque and Marc Rhainds
Unité Santé et environnement
Direction Risques biologiques, environnementaux
et occupationnels
Institut national de santé publique du Québec

ᑭᑎᑦᐸᑎᑎᒍᑦ ᖃᐅᔨᓴᕐᑐᕕᓂᖅ

> Louis Rochette
Unité Connaissance-surveillance
Direction Planification, recherche et innovation
Institut national de santé publique du Québec

ᐊᓪᓚᕐᑯᑏᑦ ᓱᓇᒥᑦᑐᑦ ᑕᒪᑐᒧᖅᒪᐅᓕᖅᒪᐊᑦ ᐊᑐᐃᓐᓇᐅᕗᑦ ᖃᓇᑕᐅᔭᑎᒍᑦ ᒪᓂᒪᑎᑕᖅᒋᑦ ***INSPQ's Web site at www.inspq.qc.ca***